Praiseldy Langi Sasongko

132 Chapter 3 65. Lanzoni M, Biffoli C, Candura F, Calizzani G, Vaglio S, Grazzini G. Plasma-derived medicinal products in Italy: information sources and flows. Blood transfusion = Trasfusione del sangue 2013; 11 Suppl 4: s13-7. 66. Lanzoni M, Candura F, Calizzani G, Biffoli C, Grazzini G. Public expenditure for plasma-derived and recombinant medicinal products in Italy. Blood transfusion = Trasfusione del sangue 2013; 11 Suppl 4: s110-7. 67. Murphy MSQ, Tinmouth A, Goldman M, et al. Trends in IVIG use at a tertiary care Canadian center and impact of provincial use mitigation strategies: 10-year retrospective study with interrupted time series analysis. Transfusion 2019. 68. O’Mahony B. The Dublin Consensus Statement 2012 on optimised supply of plasma-derived medicinal products. Blood transfusion = Trasfusione del sangue 2013; 11(4): 623-6. 69. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol 2017; 139(3S): S1-S46. 70. Shapiro RS, Borte M. 7th International Immunoglobulin Conference: Immunoglobulin in clinical practice. Clin Exp Immunol 2014; 178 Suppl 1: 86. 71. Strengers PF, Klein HG. Plasma is a strategic resource. Transfusion 2016; 56(12): 3133-7. 72. Strengers PFW. Evidence-based clinical indications of plasma products and future prospects. Annals of Blood 2017; 2: 20. 73. Watad A, Amital H, Shoenfeld Y. Intravenous immunoglobulin: a biological corticosteroid-sparing agent in some autoimmune conditions. Lupus 2017. 74. Blau IW, Conlon N, Petermann R, Nikolov N, Plesner T. Facilitated subcutaneous immunoglobulin administration (fSCIg): a new treatment option for patients with secondary immune deficiencies. Expert Rev Clin Immunol 2016; 12(7): 705-11. 75. Grazzini G, Mannucci PM, Oleari F. Plasma-derived medicinal products: demand and clinical use. Blood transfusion = Trasfusione del sangue 2013; 11 Suppl 4: s2-5. 76. Stonebraker JS, Farrugia A, Gathmann B, Orange JS. Modeling Primary Immunodeficiency Disease Epidemiology and Its Treatment to Estimate Latent Therapeutic Demand for Immunoglobulin. Journal of Clinical Immunology 2014; 34(2): 233-44. 77. Stonebraker JS, Hajjar J, Orange JS. Latent therapeutic demand model for the immunoglobulin replacement therapy of primary immune deficiency disorders in the USA. Vox Sang 2018. 78. Farrugia A, Bansal M, Marjanovic I. Estimation of the latent therapeutic demand for immunoglobulin therapies in autoimmune neuropathies in the United States. Vox Sang 2021. 79. Cheraghali AM, Abolghasemi H. Improving availability and affordability of plasma-derived medicines. Biologicals 2010; 38(1): 81-6. 80. Farrugia A, Evers T, Falcou PF, Burnouf T, Amorim L, Thomas S. Plasma fractionation issues. Biologicals 2009; 37(2): 88-93. 81. Flanagan P. Self-sufficiency in plasma supply. Vox Sanguinis 2017; Conference. 82. Godin G, Germain M. Predicting first lifetime plasma donation among whole blood donors. Transfusion 2013; 53 Suppl 5: 157S-61S. 83. Rautonen J. Self-sufficiency, free trade and safety. Biologicals 2010; 38(1): 97-9. 84. Späth PJ, Schneider C, von GS. Clinical Use and Therapeutic Potential of IVIG/SCIG, Plasma-Derived IgA or IgM, and Other Alternative Immunoglobulin Preparations. Arch Immunol Ther Exp (Warsz ) 2017; 65(3): 215-31. 85. Veldhuizen I, van DA. Motivational differences between whole blood and plasma donors already exist before their first donation experience. Transfusion 2013; 53(8): 1678-86. 86. HealthCanada. Protecting Access to Immune Globulins for Canadians: Final Report of the Expert Panel on Immune Globulin Product Supply and Related Impacts in Canada, 2018. 87. Ducruet T, Levasseur MC, Des Roches A, Kafal A, Dicaire R, Haddad E. Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center. J Allergy Clin Immunol 2013; 131(2): 585-7.e1-3. 88. Grabowski HG, Manning RL. An Economic Analysis of Global Policy Proposals to Prohibit Compensation of Blood Plasma Donors. International Journal of the Economics of Business 2016; 23(2): 149-66.

RkJQdWJsaXNoZXIy MTk4NDMw